These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19853907)

  • 1. Gastrointestinal hormones and weight management.
    Bray GA
    Lancet; 2009 Nov; 374(9701):1570-1. PubMed ID: 19853907
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapy of obesity with liraglutide. NN8022-1807 study].
    Scherbaum WA; Nitschmann S
    Internist (Berl); 2010 Aug; 51(8):1064-6. PubMed ID: 20628715
    [No Abstract]   [Full Text] [Related]  

  • 3. Liraglutide for weight loss in obese people.
    Thum T; Anker SD
    Lancet; 2010 Feb; 375(9714):551-2; author reply 552-3. PubMed ID: 20159285
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.
    Astrup A; Rössner S; Van Gaal L; Rissanen A; Niskanen L; Al Hakim M; Madsen J; Rasmussen MF; Lean ME;
    Lancet; 2009 Nov; 374(9701):1606-16. PubMed ID: 19853906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liraglutide in the treatment of obesity.
    Ng SY; Wilding JP
    Expert Opin Biol Ther; 2014 Aug; 14(8):1215-24. PubMed ID: 24905058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1 agonists.
    Padwal R
    BMJ; 2012 Jan; 344():d7282. PubMed ID: 22236410
    [No Abstract]   [Full Text] [Related]  

  • 7. Liraglutide therapy in obese people with type 2 diabetes - experience of a weight management centre.
    Elkhenini H; New JP; Summers LK; Syed AA
    Eur J Intern Med; 2014 Mar; 25(3):e38-9. PubMed ID: 24412647
    [No Abstract]   [Full Text] [Related]  

  • 8. [GLP-1 agonist supports weight loss].
    Weiß M
    MMW Fortschr Med; 2016 Feb; 158(2):71. PubMed ID: 26961053
    [No Abstract]   [Full Text] [Related]  

  • 9. Liraglutide for weight loss in obese people.
    Hallberg P; Schwan S; Melhus H
    Lancet; 2010 Feb; 375(9714):551; author reply 552-3. PubMed ID: 20159284
    [No Abstract]   [Full Text] [Related]  

  • 10. Liraglutide: A New Option for the Treatment of Obesity.
    Nuffer WA; Trujillo JM
    Pharmacotherapy; 2015 Oct; 35(10):926-34. PubMed ID: 26497479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The pharmacological treatment of obesity: past, present and future].
    Simonyi G; Pados G; Medvegy M; Bedros JR
    Orv Hetil; 2012 Mar; 153(10):363-73. PubMed ID: 22370224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.
    Wadden TA; Hollander P; Klein S; Niswender K; Woo V; Hale PM; Aronne L;
    Int J Obes (Lond); 2013 Nov; 37(11):1443-51. PubMed ID: 23812094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. liraglutide (SAXENDA⁰) and obesit. Still no satisfactory weight loss drugs.
    Prescrire Int; 2016 Jan; 25(167):5-8. PubMed ID: 26942248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
    Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
    JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacotherapy for obesity].
    Bruun JM
    Ugeskr Laeger; 2016 Oct; 178(44):. PubMed ID: 27808050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog.
    Gydesen S; Andreassen KV; Hjuler ST; Hellgren LI; Karsdal MA; Henriksen K
    Am J Physiol Endocrinol Metab; 2017 Nov; 313(5):E598-E607. PubMed ID: 28292761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
    Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
    Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity Epidemic: Pharmaceutical Weight Loss.
    Curry SA
    R I Med J (2013); 2017 Mar; 100(2):18-20. PubMed ID: 28246654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orlistat on plasma lipids and body weight reduction: A really effective drug?
    Khazaei S; Hanis SM; Mansori K
    Pharmacol Res; 2017 Sep; 123():26. PubMed ID: 28648737
    [No Abstract]   [Full Text] [Related]  

  • 20. [Beyond glycemic control in type 2 diabetes. Promises and gambles of therapy with glucagon-like peptide-1 receptor agonists].
    Mannucci E
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):3-4. PubMed ID: 22158420
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.